Journal article
Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD.
Abstract
SOURCE CITATION: Bonaca MP, Wiviott SD, Zelniker TA, et al. Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58. Circulation. 2020;142:734-47. 32795086.
Authors
Hao Q; Guyatt G
Journal
Annals of Internal Medicine, Vol. 174, No. 1,
Publisher
American College of Physicians
Publication Date
January 2021
DOI
10.7326/acpj202101190-010
ISSN
1056-8751